Hybrisan Ltd
Registered name: HYBRISAN LTD
Part of The Davidson No 2 Discretionary Settlement 2021 groupHybrisan Ltd does not publish its revenue or profit. Its accounts to 31 Aug 2025 show net assets of £33.8k and 4 employees.
Hybrisan Ltd did not publish its revenue or profit — small companies aren’t required to file a profit & loss account. Its accounts for the year to 31 Aug 2025 showed net assets of £33.8k and 4 employees. The company is classified under “research and experimental development on biotechnology” and is based in Hereford; we hold 4 years of its filed accounts.
- Status
- Active
- Location
- Hereford, West Midlands
- Age
- 13 yrs · since 2013
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.
Key figures
Revenue not disclosed
Hybrisan Ltd’s accounts for the year to 31 Aug 2025 contain a balance sheet but no profit & loss account, so its revenue and profit are not public. UK small and micro-entity companies are not required to publish a P&L — this is normal and says nothing about how the business is performing.
We never estimate revenue. Below you’ll find the balance-sheet figures that were filed — useful as indirect signals of momentum, but they are not revenue or profit.
- Employees
- 4
- Net assets
- £33.8k
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Aug 2022 | 31 Aug 2023 | 31 Aug 2024 | 31 Aug 2025 |
|---|---|---|---|---|
| Disclosure | No P&L | No P&L | No P&L | No P&L |
| Profit & loss | ||||
| Revenue (turnover) | — | — | — | — |
| Profit (best available) | — | — | — | — |
| Employees (average) | 6 | 6 | 5 | 4 |
| Ratios | ||||
| Profit margin | — | — | — | — |
| Growth (year on year) | ||||
| Headcount growth | — | 0% | ▼16.7% | ▼20% |
| Balance sheet — indirect signals, not revenue | ||||
| Cash at bank | £41.2k | £10.9k | £8.7k | £46.1k |
| Net assets | £204k | −£6.2k | −£80k | £33.8k |
| Fixed assets | £232k | £98.2k | £67.6k | £53.5k |
| Current assets | £231k | £234k | £337k | £398k |
| Debtors | £1.1k | £104 | £86 | £75 |
| Source | FullAccounts · bulk data May 2024 | FullAccounts · bulk data May 2024 | FullAccounts · bulk data Jun 2025 | FullAccounts · bulk data May 2026 |
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- —
- Now £33.8k
- Cash at bank
- ▲429%
- Now £46.1k
- Headcount
- ▼20%
- Now 4
- Deferred income
- —
- Now —
- Fixed assets
- ▼21%
- Now £53.5k
Group structure
Ownership chain
- The Davidson No 2 Discretionary Settlement 2021 (registered outside the UK register)ultimate parent50–75%
- Foxgrove Securities Limited75–100%
- Eumar Technology Limited75–100%
- Universal Synergistic Holdings Limited75–100%
- Hybrisan Ltdthis company
Bands show the share of ownership each company holds in the one below it.
From the Persons with Significant Control register (corporate controllers only).
Similar profitable businesses
- Astex Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £404m
- Profit
- £283m
- Staff
- 183
- Amphista Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £33.9m
- Profit
- £19.8m
- Staff
- 56
- Charles River U.K. LimitedKent · Research and experimental development on biotechnology
- Revenue
- £22.2m
- Profit
- £18.8m
- Staff
- 129
- Qiagen Manchester LimitedManchester · Research and experimental development on biotechnology
- Revenue
- £53.7m
- Profit
- £11.8m
- Staff
- 239
- Alchemab Therapeutics LtdLondon · Research and experimental development on biotechnology
- Revenue
- £30m
- Profit
- £8.3m
- Staff
- 55
- Ligand UK Development LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £8.7m
- Profit
- £6m
- Staff
- —
Sources
Latest figures from FullAccounts for the year to 31 Aug 2025, from the Companies House accounts bulk data published May 2026. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.